Insilico Medicine names preclinical candida
Insilico Medicine (“Insilico”), a clinical-stage, end-to-end, artificial intelligence (AI)-driven drug discovery company, today announced that the company’s drug discovery team has nominated a preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapies using its end-to-end Pharma.AI platform. The company has now nominated eight preclinical candidates for 2022. According to statistics published by the International Agency …